13F Holdings
中文EN

LBRX LB PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1691082 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-650.9%
TTM EPS YoY94.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-38.8%
ROA-36.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets7.9%
Debt / equity0.00x
Current ratio14.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$16.74M$51.17M
SG&A expense$13.66M$13.66M
Pretax income-$25.20M-$63.10M
Income tax$1,000$1,000
Net income-$25.20M-$63.10M
EPS (basic)-3.13-176.15
EPS (diluted)-3.13-176.15
Weighted avg. shares (diluted)8.05M358,229
Balance sheet
Cash & equivalents$250.17M$22.98M
Short-term investments$45.04M$5.02M
Current assets$308.43M$28.88M
PP&E, net$1.58M$1.86M
Total assets$312.93M$33.53M
Current liabilities$7.44M$8.11M
Total liabilities$11.62M$13.83M
Shareholders' equity$301.31M-$94.55M
Shares outstanding25.30M251,655
Cash flow statement
Operating cash flow-$35.21M-$53.05M
Capital expenditure$52,000$769,000
Free cash flow-$35.26M-$53.82M
Investing cash flow-$39.89M$23.23M
Financing cash flow$302.56M$38.31M
Depreciation & amortization$321,000$91,000
Stock-based compensation$4.19M$3.09M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.